{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhou T"],"funding":["NIAID NIH HHS","NCI NIH HHS","NIH HHS"],"pagination":["2594"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11274508"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(14)"],"pubmed_abstract":["Antiandrogen is part of the standard-of-care treatment option for metastatic prostate cancer. However, prostate cancers frequently relapse, and the underlying resistance mechanism remains incompletely understood. This study seeks to investigate whether long non-coding RNAs (lncRNAs) contribute to the resistance against the latest antiandrogen drug, darolutamide. Our RNA sequencing analysis revealed significant overexpression of LOC730101 in darolutamide-resistant cancer cells compared to the parental cells. Elevated LOC730101 levels were also observed in clinical samples of metastatic castration-resistant prostate cancer (CRPC) compared to primary prostate cancer samples. Silencing LOC730101 with siRNA significantly impaired the growth of darolutamide-resistant cells. Additional RNA sequen"],"journal":["Cancers"],"pubmed_title":["LncRNA LOC730101 Promotes Darolutamide Resistance in Prostate Cancer by Suppressing miR-1-3p."],"pmcid":["PMC11274508"],"funding_grant_id":["P30 CA046934","1R33AI133697-03A1","R33 AI133697","R01 CA211861","1R01CA211861-05A1"],"pubmed_authors":["Wu J","Nguyen S","Zhou T","He B","Feng Q"],"additional_accession":[]},"is_claimable":false,"name":"LncRNA LOC730101 Promotes Darolutamide Resistance in Prostate Cancer by Suppressing miR-1-3p.","description":"Antiandrogen is part of the standard-of-care treatment option for metastatic prostate cancer. However, prostate cancers frequently relapse, and the underlying resistance mechanism remains incompletely understood. This study seeks to investigate whether long non-coding RNAs (lncRNAs) contribute to the resistance against the latest antiandrogen drug, darolutamide. Our RNA sequencing analysis revealed significant overexpression of LOC730101 in darolutamide-resistant cancer cells compared to the parental cells. Elevated LOC730101 levels were also observed in clinical samples of metastatic castration-resistant prostate cancer (CRPC) compared to primary prostate cancer samples. Silencing LOC730101 with siRNA significantly impaired the growth of darolutamide-resistant cells. Additional RNA sequen","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-04-08T19:20:36.954Z","creation":"2025-04-19T13:10:33.618Z"},"accession":"S-EPMC11274508","cross_references":{"pubmed":["39061232"],"doi":["10.3390/cancers16142594"]}}